PLG0206 is an engineered antimicrobial peptide that has completed phase 1 clinical studies. A prospective study was completed on explanted implants from chronic periprosthetic joint infections ( = 17). At a concentration of 1 mg/mL for 15 min, there was a mean 4-log reduction (range, 1 to 7) in the bacterial CFU identified from the implants. Chronically infected prosthetics of the knee were exposed to PLG0206, an engineered antimicrobial peptide, at a concentration of 1 mg/mL for 15 min. A mean 4-log reduction (range, 1 to 7) in the number of bacteria occurred, which may translate to improved clinical outcomes for persons with prosthetic joint infection of the knee.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612143 | PMC |
| http://dx.doi.org/10.1128/Spectrum.01879-21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class.
PLoS One
September 2022
Department of Orthopedic Surgery, Arthritis and Arthroplasty Design Group, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Article Synopsis
- There is a global public health crisis due to the lack of new antibiotics for drug-resistant and biofilm-associated infections, leading to a need for innovative solutions.
- Researchers have developed PLG0206, an engineered antimicrobial peptide, which overcomes challenges of size, toxicity, and effectiveness against multidrug-resistant (MDR) pathogens.
- PLG0206 has shown promising results in laboratory and animal models, demonstrating broad-spectrum effectiveness and potential for continued clinical development in treating various infections.
Evolved resistance to a novel cationic peptide antibiotic requires high mutation supply.
Evol Med Public Health
May 2022
Department of Microbiology and Molecular Genetics, and Center for Evolutionary Biology and Medicine, University of Pittsburgh, Pittsburgh, PA, 15219 USA.
Background And Objectives: A key strategy for resolving the antibiotic resistance crisis is the development of new drugs with antimicrobial properties. The engineered cationic antimicrobial peptide WLBU2 (also known as PLG0206) is a promising broad-spectrum antimicrobial compound that has completed Phase I clinical studies. It has activity against Gram-negative and Gram-positive bacteria including infections associated with biofilm.
View Article and Find Full Text PDFThe Engineered Antibiotic Peptide PLG0206 Eliminates Biofilms and Is a Potential Treatment for Periprosthetic Joint Infections.
Antibiotics (Basel)
December 2021
Peptilogics, 2730 Sidney Street, Suite 300, Pittsburgh, PA 15203, USA.
Antimicrobial peptides (AMPs) have recently gained attention for their potential to treat diseases related to bacterial and viral infections, as many traditional antimicrobial drugs have reduced efficacy in treating these infections due to the increased prevalence of drug-resistant pathogens. PLG0206, an engineered cationic antibiotic peptide that is 24 residues long, has been designed to address some limitations of other natural AMPs, such as toxicity and limited activity due to pH and ion concentrations. Nonclinical studies have shown that PLG0206 is highly selective for targeting bacterial cells and is not toxic to human blood cells.
View Article and Find Full Text PDFProspective Activity of PLG0206, an Engineered Antimicrobial Peptide, on Chronic Periprosthetic Joint Infection Total Knee Arthroplasty Components : The Knee Explant Analysis (KnEA) Study.
Microbiol Spectr
December 2021
Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburghgrid.21925.3d, Pittsburgh, Pennsylvania, USA.
PLG0206 is an engineered antimicrobial peptide that has completed phase 1 clinical studies. A prospective study was completed on explanted implants from chronic periprosthetic joint infections ( = 17). At a concentration of 1 mg/mL for 15 min, there was a mean 4-log reduction (range, 1 to 7) in the bacterial CFU identified from the implants.
View Article and Find Full Text PDFA Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of a First-in-Human Engineered Cationic Peptide, PLG0206, Intravenously Administered in Healthy Subjects.
Antimicrob Agents Chemother
January 2022
Peptilogics, Pittsburgh, Pennsylvania, USA.
In this first-in-human study, PLG0206, a novel engineered cationic antimicrobial peptide, was evaluated for safety, tolerability, and pharmacokinetics (PK) when intravenously (i.v.) administered as a single dose to healthy subjects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!